Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Engineered (modified) OV face significant development issues

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 31, 2022 12:53pm

123 Views

Post# 35060476

RE:RE:RE:Engineered (modified) OV face significant development issues

Any application of mRNA-based cancer vaccines is not seen in the forseeable future due to several development chanllenges/problems already discussed including the instability of mRNA, immunogenicity, the inefficiency of in-vivo delivery, the personalization of the therapy, the time to process the patient's neoantigens into a bespoke cancer vaccine (1-2 months), and the inablity to reach economies of scale in multiple/diverse cancer tumors.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1